E7 TCR-T / Rutgers University - LARVOL DELTA

Liquid biopsy detects treatment resistance to T cell receptor (TCR)-T cell therapy (SITC 2025) - P1/2 | "Practical limitations of tumor biopsy acquisition pose a challenge to studying the frequency and timing of these resistance mechanisms.5 6 Conversely, liquid biopsy offers a minimally invasive and easily repeatable method for real-time monitoring of tumors difficult or inaccessible to biopsy.7 8 This study aimed to determine if HLA-A*02:01 damaging mutations previously identified in tumor biopsies from 2 patients treated in a phase I trial of E7 TCR-T cell therapy for HPV-associated cancers could also be detected with liquid biopsy.3Methods Archived plasma specimens collected before and after treatment from each of the 2 patients (Patients 4 and 5) were studied. This method holds promise for prospectively predicting response and monitoring for the development of resistance to TCR-based therapeutics.Ethics Approval The trial was registered on clinicaltrials.gov, trial number NCT02858310. This study was approved by the NIH IRB; approval number 16C0154."

Biopsy • IO biomarker • Liquid biopsy • Melanoma • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • HLA-A